Watchlist

Watchlist
Apricus Biosciences, Inc. (APRI)
Apricus Biosciences, Inc. (APRI)
Apricus Bio has work to do before refiling U.S. marketing application for ED cream Vitaros; shares down 10% premarket
Nano cap Apricus Biosciences (NASDAQ: APRI ) slips 10% premarket on light volume on the heels of FDA feedback that it needs to develop a new less-concentrated formulation of erectile dysfunction (ED) cream Vitaros (alprostadil, DDAIP.HCL) and conduct two new Phase 3 studies wit…
Key events next week - healthcare
Noteworthy events during the week of April 8 - 14 for healthcare investors. More news on: Avita Medical Ltd., Immunovaccine Inc., Intercept Pharmaceuticals, Healthcare stocks news, , Read more …
Understanding Binary Catalysts: A Brief Guide For Biotech Investors
This article was co-authored by Stepan Lavrouk. Stepan is an investment analyst with Almington Capital. We have written extensively on Seeking Alpha about a range of biotech stocks. But we have also spent some time addressing the activity of biotech investing itself. In previous articles…
Apricus Biosciences -27% on offering of stock, warrants
Apricus Biosciences (NASDAQ: APRI ) is off 26.7% after hours following word of a public offering of common stock and warrants . More news on: Apricus Biosciences, Inc, Healthcare stocks news, Stocks on the move, Read more …
Update On February Biotech Catalysts: What Happened And What's Next
On January 31 st , I published an article discussing major catalysts facing three interesting developmental biotech companies: Dynavax Technologies ( DVAX ), Novavax ( NVAX ), and Puma Biotechnology ( PBYI ). I followed that up shortly after with an article on one more biotech with a crucia…
Apricus Biosciences' (APRI) CEO Rich Pascoe on Q4 2017 Results - Earnings Call Transcript
Apricus Biosciences, Inc. (APRI) Q4 2017 Earnings Conference Call March 1, 2018 4:30 PM ET Executives Matt Beck Vice President-The Trout Group LLC Rich Pascoe Chief Executive Officer, Principal Accounting Officer, Secretary and Director Kelly Deck Execu…
Apricus Biosciences misses by $0.84
Apricus Biosciences (NASDAQ: APRI ): Q4 EPS of -$0.99 misses by $0.84 . Press Release More news on: Apricus Biosciences, Inc, Earnings news and commentary, Healthcare stocks news, ,
3 Things In Biotech You Should Learn Today: February 19, 2018
Note: Subscribers to Avisol Capital Partners Total Pharma Tracker got an early look at this publication. Welcome to another edition of "3 Things In Biotech You Should Learn Today," a daily digest dedicated to helping you keep pace with the fast-moving world of pharmaceutical and biotec…
Midday Gainers / Losers (2/20/2018)
Gainers: FOGO +25% . VYGR +22% . DIN +21% . DCAR +21% . ACHV +19% . DPW +16% . APRI +17% . ECYT +14% . DQ +13% . AVGR +13% . More news on: Fogo de Chao, Voyager Therapeutics, Dine Brands Global, Inc., Stocks on the move, , Read more …
Midday Gainers / Losers (2/16/2018)
Gainers: XTNT +54% . FTFT +25% . SNCR +22% . GEN +20% . CALA +21% . ATOM +20% . MULE +18% . NVAX +14% . NAVG +14% . CATB +14% . More news on: Xtant Medical Holdings, Inc., Future Fintech Group Inc, Synchronoss Technologies, Inc., Stocks on the move, , R…
Apricus Biosciences, Inc. (APRI)